Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 2/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.35 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27819587 | 0.81 | CTSK (0.54) | CTSKKMT2AAURKBMALT1KDM4E | |
| SCHEMBL1926851 | 0.78 | PLK1 (0.60) | PLK1AURKBAURKA | |
| SCHEMBL1926852 | 0.78 | PLK1 (0.60) | PLK1AURKBAURKA | |
| SCHEMBL1926344 | 0.78 | PLK1 (0.60) | PLK1AURKBAURKA | |
| SCHEMBL3451280 | 0.78 | CTSK (0.58) | CTSKKMT2AAURKBMALT1KDM4E | |
| SCHEMBL1926410 | 0.77 | PLK1 (0.52) | PLK1AURKBAURKA | |
| SCHEMBL19174443 | 0.76 | CTSK (0.60) | CTSKKMT2AAURKBMALT1KDM4E | |
| SCHEMBL1926390 | 0.75 | PLK1 (0.65) | PLK1AURKBAURKA | |
| SCHEMBL17544472 | 0.74 | MALT1 (0.57) | CTSKKMT2AMALT1KDM4EALDH1A1 | |
| SCHEMBL1925894 | 0.73 | PLK1 (0.57) | PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7956185-B2 | Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases | ABBOTT LABORATORIES (US) | 2011-06-07 | — | — | US | disclosed |
| EP-2021316-A1 | INHIBITORS OF POLO-LIKE KINASES | Abbott Laboratories (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080015192-A1 | INHIBITORS OF POLO-LIKE KINASES | ABBVIE INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007140233-A1 | INHIBITORS OF POLO-LIKE KINASES | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015192-A1 | INHIBITORS OF POLO-LIKE KINASES | PLK1, PLK2, BUB1B | CCR6 4323/4885CTSK 691/4885MAPK8 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.